Ferri, Nicola

Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Fogacci, F., Ferri, N., Toth, P. P., Ruscica, M., Corsini, A., & Cicero, A. F. G. (2019) · Drugs

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 132

Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages

Adorni, M. P., Cipollari, E., Favari, E., Zanotti, I., Zimetti, F., Corsini, A., Ricci, C., Bernini, F., & Ferri, N. (2017) · Atherosclerosis

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 130

Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease

Zimetti, F., Caffarra, P., Ronda, N., Favari, E., Adorni, M. P., Zanotti, I., Bernini, F., Barocco, F., Spallazzi, M., Galimberti, D., et al. (2016) · Journal of Alzheimer's Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 75

Lipid Lowering Drugs: Present Status and Future Developments

Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 73

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease

Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019) · Frontiers in Aging Neuroscience

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 67

Depression and cardiovascular risk-association among Beck depression inventory, PCSK9 levels and insulin resistance

Macchi, C., Favero, C., Ceresa, A., Vigna, L., Conti, D. M., Pesatori, A. C., Racagni, G., Corsini, A., Ferri, N., Sirtori, C. R., et al. (2020) · Cardiovascular Diabetology

Diabetes, Cardiovascular Risks, and LipoproteinsCardiac Health and Mental Health

Cited by 51

PCSK9 ablation attenuates Aβ pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice

Vilella, A., Bodria, M., Papotti, B., Zanotti, I., Zimetti, F., Remaggi, G., Elviri, L., Potì, F., Ferri, N., Lupo, M. G., et al. (2024) · Brain, Behavior, and Immunity

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 43

PCSK9 affects astrocyte cholesterol metabolism and reduces neuron cholesterol supplying in vitro: potential implications in Alzheimer’s disease

Papotti, B., Adorni, M. P., Marchi, C., Zimetti, F., Ronda, N., Panighel, G., Lupo, M. G., Vilella, A., Giuliani, D., Ferri, N., et al. (2022) · International Journal of Molecular Sciences

Alzheimer's disease research and treatmentsCholesterol and Lipid Metabolism

Cited by 41

REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study

De Martin, S., Gabbia, D., Folli, F., Bifari, F., Fiorina, P., Ferri, N., Stahl, S., Inturrisi, C. E., Pappagallo, M., Traversa, S., et al. (2021) · Frontiers in Pharmacology

Treatment of Major DepressionNerve injury and regeneration

Cited by 28

Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localization

Pelucchi, S., Da Dalt, L., De Cesare, G., Stringhi, R., D’Andrea, L., La Greca, F., Cambria, C., Vandermeulen, L., Zianni, E., Musardo, S., et al. (2025) · Pharmacological Research

Neuroscience and Neuropharmacology ResearchAlzheimer's disease research and treatments

Cited by 12

Effect of natural and synthetic PCSK9 inhibitors on Alzheimer’s disease-related parameters in human cerebral cell models

Ugolotti, M., Papotti, B., Adorni, M. P., Giannessi, L., Rossi, I., Lupo, M. G., Panighel, G., Ferri, N., Kukula-Koch, W., Vilella, A., et al. (2024) · Atherosclerosis

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 1